Accessibility Menu

Eli Lilly (LLY -0.88%) and Novo Nordisk (NVO -1.92%) agreed to lower prices for their weight loss treatments in exchange for lower tariffs and expanded access.

*Stock prices used were the afternoon prices of Nov. 5, 2025. The video was published on Nov. 7, 2025.

Read Next

About the Author

Parkev Tatevosian, CFA
A Fool since 2019, and a graduate of Cal State LA with a B.S. in Finance and M.A. in Economics. Parkev is an adjunct professor of Finance and enjoys reading about financial and economic history. You'll often find him writing about stocks in the consumer goods and technology sectors.
TMFParkev
X@TMFParkev

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

Stocks Mentioned

Novo Nordisk Stock Quote
Novo Nordisk
NYSE: NVO
$46.60
(-1.92%)-$0.91
Stock Advisor

Motley Fool Stock Advisor’s Latest Pick

Get Access
---% Avg Return
Eli Lilly Stock Quote
Eli Lilly
NYSE: LLY
$1,149.36
(-0.88%)-$10.24

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services